The primary differences are solubility and formulation compatibility. Phenibut HCL is highly water-soluble (~200 mg/mL) and suited to aqueous solution preparation. Phenibut Free Amino Acid (free base) has lower water solubility (~10–15 mg/mL) but higher solubility in organic solvents and lipophilic vehicles.

The free base form is preferred for lipophilic formulations, sublingual preparations, or when chloride ions from the HCL salt would confound the assay. Pharmacological activity is equivalent once dissolved; the choice is driven by formulation requirements.

Once absorbed, both forms deliver the same active moiety (β-phenyl-GABA) to the systemic circulation. The salt form has no independent pharmacological activity — the HCl component dissociates in solution. Any pharmacokinetic differences relate to dissolution rate and absorption site pH dynamics rather than inherent compound differences.

In vivo, both forms are expected to produce equivalent plasma concentration profiles at equimolar doses when formulated appropriately.

Phenibut has a pKa of approximately 4.1 (carboxylic acid) and 9.4 (amino group). At physiological pH (~7.4), it exists predominantly in its zwitterionic form. The free base powder is in its neutral/free base state, which has lower water solubility than the protonated HCL salt form. Solubility increases significantly below pH 5, where protonation of the amino group occurs.

This pH-dependent solubility is relevant to in vitro assay design when working in acidic culture conditions or buffer systems.